Evaluation of verteporfin pharmakokinetics - redefining the need of photosensitizers in ophthalmology

Introduction: The benzoporphyrine derivative verteporfin has lost its importance to the treatment of the most frequent neovascular eye diseases. Nevertheless, it is still mandatory to define the remaining applications, role, and potential of verteporfin in ocular photodynamic therapy (PDT), includin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert opinion on drug metabolism & toxicology Jg. 8; H. 8; S. 1023 - 1041
Hauptverfasser: Ziemssen, Focke, Heimann, Heinrich
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Informa UK, Ltd 01.08.2012
Taylor & Francis
Schlagworte:
central serous chorioretinopathy
Central Serous Chorioretinopathy - drug therapy
Central Serous Chorioretinopathy - physiopathology
Choroid Neoplasms - drug therapy
Choroid Neoplasms - physiopathology
choroidal haemangioma
choroidal melanoma
choroidal neovascularization
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - physiopathology
Drug Evaluation
Hemangioma - drug therapy
Hemangioma - physiopathology
Humans
low fluence
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - physiopathology
Ophthalmology - methods
Photochemotherapy - methods
Photosensitizing Agents - pharmacokinetics
Photosensitizing Agents - pharmacology
polypoidal choroidal vasculopathy
Porphyrins - pharmacokinetics
Porphyrins - pharmacology
Randomized Controlled Trials as Topic
retinal angioma
Treatment Outcome
verteporfin
ISSN:1742-5255, 1744-7607, 1744-7607
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: The benzoporphyrine derivative verteporfin has lost its importance to the treatment of the most frequent neovascular eye diseases. Nevertheless, it is still mandatory to define the remaining applications, role, and potential of verteporfin in ocular photodynamic therapy (PDT), including the dosages of administration, effectiveness, and safety profile. Areas covered: Although verteporfin PDT has forfeited the first-line status and value of treating subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration or pathologic myopia, the treatment remains the standard of care for choroidal haemangioma and polypoidal choroidal vasculopathy. PDT is effective in less pigmented choroidal melanoma as well as in retinal vascular proliferations and retinal angioma. Verteporfin was granted the orphan drug designation for the treatment of chronic or recurrent central serous chorioretinopathy (CSC). Expert opinion: Evidence-based data regarding optimized parameters (low fluence, reduced dose, fractionated irradiation) adapted to the treated diseases (target structure, dosimetry, blood supply) are scarce. Prospective and large clinical trials are missing, although the scientific community agrees on the fact that the standard treatment protocol does not necessarily provide the optimal efficacy to the specific disease or individual patient. Within the reviewed indications, the adverse effect profile is favorable compared with other therapies.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1742-5255
1744-7607
1744-7607
DOI:10.1517/17425255.2012.701617